NCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
Stanford University
Thomas Jefferson University
University Medical Center Groningen
University of Southern California
University of Parma
Case Comprehensive Cancer Center
Stanford University
Vanderbilt-Ingram Cancer Center